GridAI Technologies Corp.
GRDX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GRDX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GRDX
GridAI Technologies Corp. (GRDX) is a diversified holding company with legacy biopharmaceutical assets (Adrulipase) and recently acquired software-enabled energy orchestration businesses (Grid AI Corp. and AMPX), currently facing substantial doubt about its ability to continue as a going concern.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for GridAI Technologies Corp..
GridAI Technologies Corp. (GRDX) is a diversified holding company with legacy biopharmaceutical assets (Adrulipase) and recently acquired software-enabled energy orchestration businesses (Grid AI Corp. and AMPX), currently facing substantial doubt about its ability to continue as a going concern.
- Cash and equivalents of $1.4M as of 2026-06-30 [sec].
- Shareholders' equity of -$6.3M and total debt of $1.7M as of 2026-06-30 [sec].
- Total revenue of $0.1M as of 2026-06-30 [sec].
- Acquired Grid AI Corp. in 2025, expanding into software-enabled energy orchestration and grid-edge platforms [sec_mda · as of 2026-05-01].
- Legacy biopharmaceutical asset Adrulipase remains the principal retained asset, but advancement would require substantial additional capital [sec_mda · as of 2026-05-27].
What works
- The company is evaluating all potential strategic options, including a merger, reverse merger, sale, or other transaction, which could provide a path to value [sec · filed 2026-05-28].
- The acquisition of Grid AI Corp. and AMPX diversifies operations beyond legacy life sciences into energy orchestration, a potentially growing sector [sec_mda · as of 2026-05-01].
What to weigh
- The company has substantial doubt about its ability to continue as a going concern, with negative shareholders' equity of -$6.3M and minimal revenue [sec_mda · as of 2025-11-19] [sec].
- Cash and equivalents of only $1.4M as of 2026-06-30 provide limited runway, and the company expects to continue incurring substantial expenditures [sec] [sec_mda · as of 2026-05-27].
- The legacy biopharmaceutical asset Adrulipase requires significant capital for further development, which the company currently lacks [sec_mda · as of 2026-05-27].
- There is no assurance that the strategic review process will result in a successful transaction or any cash distributions to stockholders [sec · filed 2026-05-28].
From the filings
Quoted directly from source documents.
Substantial doubt about going concern
“We believe these conditions may raise substantial doubt about our ability to continue as a going concern.”
SEC MD&A · November 19, 2025
Strategic alternatives being evaluated
“We are evaluating all potential strategic options, including a merger, reverse merger, sale, wind-down, liquidation and dissolution or other strategic transaction.”
SEC filings · May 28, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern due to negative equity and minimal revenue [sec_mda · as of 2025-11-19].
- Limited cash runway — Cash of $1.4M as of 2026-06-30 is insufficient to fund operations without additional financing [sec].
- No assurance of strategic outcome — No guarantee that the strategic review will result in a transaction or value for stockholders [sec · filed 2026-05-28].
- Capital needs for Adrulipase — Advancing Adrulipase requires substantial capital for manufacturing and clinical trials, which is not currently available [sec_mda · as of 2026-05-27].
What to watch
- Outcome of the strategic review process, including potential merger, sale, or liquidation [sec · filed 2026-05-28].
- Ability to raise additional capital through equity or debt financings [sec_mda · as of 2025-11-19].
- Progress or lack thereof on the legacy Adrulipase program [sec_mda · as of 2026-05-27].
- Integration and performance of the Grid AI Corp. and AMPX energy businesses [sec_mda · as of 2026-05-01].
Sources: SEC filings · SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run GridAI Technologies Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GridAI Technologies Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
3.3 months
OCF -$2M
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$732K
| Holder | Shares | Value |
|---|---|---|
| renaissance technologies llc | 183,800 | $371K |
| federation des caisses desjardins du quebec | 47,800 | $97K |
| vanguard capital management llc | 36,586 | $74K |
| geode capital management, llc | 33,270 | $67K |
| state street corp | 23,446 | $47K |
| vanguard fiduciary trust co | 16,345 | $33K |
| jane street group, llc | 12,657 | $26K |
| harbour investments, inc. | 7,994 | $16K |
| sbi securities co., ltd. | 504 | $1K |
| osaic holdings, inc. | 1 | $2 |
Showing top 10 of 12 institutional holders of GridAI Technologies Corp.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 1.4%
- Days to cover
- 0.6
- Shares short
- 58,762
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GRDX short interestGovernance
Frequently asked questions
What is the AI investment thesis for GridAI Technologies Corp.?
GridAI Technologies Corp. (GRDX) is a diversified holding company with legacy biopharmaceutical assets (Adrulipase) and recently acquired software-enabled energy orchestration businesses (Grid AI Corp. and AMPX), currently facing substantial doubt about its ability to continue as a going concern.
What is GridAI Technologies Corp.'s lead drug candidate?
GridAI Technologies Corp.'s most advanced tracked candidate is adrulipase (Phase 2) for Exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP).
Who is the CEO of GridAI Technologies Corp.?
Mr. Jason David Sawyer is the chief executive officer of GridAI Technologies Corp. (GRDX).
Where is GridAI Technologies Corp. headquartered?
GridAI Technologies Corp. (GRDX) is headquartered in Edinburgh, United Kingdom.
What therapeutic areas does GridAI Technologies Corp. focus on?
GridAI Technologies Corp. develops therapies across Oncology, Rare Disease, Respiratory, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.